Skip to main content

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ

Publication: Clin Chem (2008) • Vol 54 • Page 44-52PMID: 17981926View on PubMed

Purpose

The purpose of the paper was to assess the diagnostic applicability of a newly designed algorithm for the analysis of proteomic data to reliably distinguish sera of prostate cancer patients from those of healthy controls.

Conclusion

The authors identified potential sources of bias due to biospecimen storage that compromised a valid analysis of the designed SELDI-TOF MS analytical algorithm, suggesting that the duration of frozen storage and the number of freeze thaw cycles may adversely affect the proteomic profile of serum samples.

Studies (1)

Purpose

The purpose of the study was to assess the diagnostic applicability of a newly designed algorithm for the analysis of proteomic data to reliably distinguish sera of prostate cancer patients from those of healthy controls. The algorithm used in this study was based on the analysis of serum samples from 181 patients with prostate cancer, 143 patients with benign prostatic hyperplasia and 220 normal control and was validated with serum from a separate cohort of 42 prostate cancer patients and 42 controls without prostate cancer. All specimens were aliquoted and aliquots of each specimen were sent to six different SELDI-TOF mass spectrometry for analysis. Specimens in the validation cohort were used for a blinded analysis and then assigned to a group based on the decision algorithm.

Summary of Findings

Evaluation of the algorithm's diagnostic performance was compromised by preanalytical sample bias. Sera collected from prostate patients before 1996 exhibited different mass spectrometry profiles than those collected during or after 1996. Further, sera samples collected from prostate cancer patients during or after 1996 exhibited spectral profiles more similar to normal controls collected during the same time period than samples collected from prostate cancer patients prior to 1996. Potential confounding parameters identified by the authors included storage duration and the number of freeze thaw cycles.

  • Biospecimens

    FluidSerum
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
    NeoplasticBenign
    Normal
  • Platforms

    ProteinSELDI-TOF MS
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    StorageFreeze/thaw cycling
    1 cycle
    2 cycles
    >2 cycles
    StorageStorage duration
    7-28 yr